tdm1 breast cancer

Release time ：Dec-18,2024

T-DM1 (Trastuzumab Deruxtecan) is a targeted therapy for HER2-positive breast cancer. It integrates trastuzumab, an antibody against HER2, with a potent microtubule inhibitor, designed to more effectively eliminate cancer cells while minimizing harm to healthy cells.

Typically, T-DM1 is administered to patients whose disease has progressed despite prior HER2-directed treatments. By binding to HER2 receptors on the surface of HER2-positive cancer cells, it delivers the drug directly into the cancer cells to achieve cell death. Its precision targeting offers the advantage of increased efficacy and reduced side effects compared to traditional chemotherapy.

While T-DM1 has demonstrated significant efficacy in clinical trials, it is not indicated for all breast cancer patients. Benefits are limited to those confirmed as HER2-positive through testing. Furthermore, as a newer treatment modality, T-DM1's long-term outcomes and safety profile require further research for validation. Consequently, patients considering T-DM1 for breast cancer treatment should do so under medical supervision, with a thorough understanding of the treatment's risks and benefits, and engage in regular monitoring to evaluate treatment efficacy and adjust the therapeutic strategy as needed.